Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 11:25 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Completed Not applicable Interventional Accepts healthy volunteers Results available

Ovarian Morphology and Theca Cell Androgen Production in Women With Polycystic Ovary Syndrome (PCOS)

NCT02145247
Conditions
Polycystic Ovary Syndrome
Interventions
hCG
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 37 Years · Female only
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
La Jolla, California
Conditions
Ovarian Cancer, Breast Cancer
Interventions
Not listed
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older · Female only
Enrollment
1,452 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2018
U.S. locations
3
States / cities
New York, New York
Conditions
Childhood Germ Cell Tumor, Drug/Agent Toxicity by Tissue/Organ, Extragonadal Germ Cell Tumor, Ovarian Cancer
Interventions
bleomycin sulfate, amifostine trihydrate, cisplatin, etoposide, conventional surgery
Biological · Drug · Procedure
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 14 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2007
U.S. locations
97
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 74 more
Conditions
Ovarian Cancer
Interventions
MOv-gamma chimeric receptor gene, aldesleukin, therapeutic allogeneic lymphocytes
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Cervical Cancer, Endometrial Cancer, Ovarian Cancer
Interventions
PET-CT, MR-PET
Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Stage II Fallopian Tube Cancer AJCC v8, Stage II Ovarian Cancer AJCC v8, Stage II Primary Peritoneal Cancer AJCC v8, Stage III Fallopian Tube Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Primary Peritoneal Cancer AJCC v8, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Primary Peritoneal Cancer AJCC v8
Interventions
Behavioral Intervention, Best Practice, Biospecimen Collection, Electronic Health Record Review, Exercise Intervention, Medical Device Usage and Evaluation, Questionnaire Administration, Supportive Care
Behavioral · Other · Procedure
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Buffalo, New York
Conditions
Ovarian, Breast, SCLC, Gastric Cancers
Interventions
Olaparib, MEDI4736, Bevacizumab
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
7
States / cities
Newnan, Georgia • Towson, Maryland • Boston, Massachusetts + 4 more
Suspended No phase listed Observational Accepts healthy volunteers

Urinary DENND1A.V2 as a Predictor of Pubertal Hyperandrogenemia

NCT02611128
Conditions
Polycystic Ovary Syndrome, Hyperandrogenism, Puberty
Interventions
Phenotype/genotype assessment
Other
Lead sponsor
University of Virginia
Other
Eligibility
8 Years to 17 Years · Female only
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2024
U.S. locations
1
States / cities
Charlottesville, Virginia
Conditions
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions
carboplatin, epirubicin hydrochloride, paclitaxel, conventional surgery
Drug · Procedure
Lead sponsor
Nordic Society of Gynaecological Oncology - Clinical Trials Unit
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
1
States / cities
Duluth, Minnesota
Active, not recruiting Not applicable Interventional

Nudge to Gynecologic Oncology

NCT06451263
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
Interventions
Nudge
Behavioral
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Ovarian Cancer, Malignant Tumor of Peritoneum, Quality of Life
Interventions
Not listed
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Cancer, Ovarian, Chemotherapy Effect, Calorie Deficiency, Fasting, Intermittent
Interventions
Fasting Mimicking Diet, Chemotherapy
Other · Drug
Lead sponsor
L-Nutra Inc
Industry
Eligibility
35 Years to 70 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Knoxville, Tennessee
Conditions
Solid Tumors
Interventions
INCB057643, Gemcitabine, Paclitaxel, Rucaparib, Abiraterone, Ruxolitinib, Azacitidine
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
16
States / cities
Birmingham, Alabama • La Jolla, California • Denver, Colorado + 12 more
Conditions
Polycystic Ovary Syndrome, Anovulation, Oligoovulation, Infertility, Hyperandrogenism
Interventions
Metformin, Clomiphene citrate, Placebo
Drug
Lead sponsor
59th Medical Wing
Federal
Eligibility
18 Years to 40 Years · Female only
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1997 – 2003
U.S. locations
1
States / cities
Lackland Air Force Base, Texas
Recruiting No phase listed Observational Accepts healthy volunteers

EXoPERT EMERALD Clinical Study

NCT07186296
Conditions
Breast Cancer, Colon Cancer, Pancreatic Cancer, Ovarian Cancer, Lung Cancer
Interventions
EXoPred
Diagnostic Test
Lead sponsor
EXoPERT
Industry
Eligibility
45 Years and older
Enrollment
1,400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
9
States / cities
Long Beach, California • Los Angeles, California • Honolulu, Hawaii + 6 more
Conditions
Ovarian Cancer
Interventions
Not listed
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Ovarian Cancer
Interventions
Durvalumab, BA3011, BA3021, ENB003, Toripalimab
Drug
Lead sponsor
Canadian Cancer Trials Group
Network
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Ovarian Cancer, Peritoneal Cancer
Interventions
DCVac-L
Biological
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Ovarian Cancer
Interventions
Ipatasertib, Cobimetinib, Trastuzumab Emtansine, Atezolizumab, Bevacizumab, Paclitaxel, Giredestrant, Abemaciclib, Inavolisib, Palbociclib, Letrozole, Olaparib, Luteinizing Hormone-Releasing Hormone (LHRH) Agonists, Cyclophosphamide
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older · Female only
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
8
States / cities
San Francisco, California • St Louis, Missouri • Charlotte, North Carolina + 5 more
Conditions
Advanced or Metastatic Solid Tumors
Interventions
IPH4502
Drug
Lead sponsor
Innate Pharma
Industry
Eligibility
18 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
5
States / cities
Boston, Massachusetts • Hackensack, New Jersey • New York, New York + 2 more
Conditions
Ovarian Cancer
Interventions
Pembrolizumab, ALX148, Doxorubicin
Drug
Lead sponsor
Alexander B Olawaiye, MD
Other
Eligibility
18 Years and older · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Ovarian Cancer, Sarcoma, Small Intestine Cancer
Interventions
filgrastim, docetaxel, gemcitabine hydrochloride
Biological · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
1
States / cities
New York, New York
Conditions
Ovarian Cancer
Interventions
carboplatin, cisplatin, paclitaxel, topotecan hydrochloride
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
10
States / cities
Fresh Meadows, New York • New York, New York • The Bronx, New York + 2 more
Completed Phase 3 Interventional Results available

Pregnancy in Polycystic Ovary Syndrome II

NCT00719186
Conditions
Pregnancy, Polycystic Ovary Syndrome
Interventions
Clomiphene citrate, Letrozole
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
12
States / cities
Birmingham, Alabama • Stanford, California • Aurora, Colorado + 9 more